Summary

The 7 major neurofibrosarcoma markets are expected to exhibit a CAGR of 9.6% during 2024-2034.

The neurofibrosarcoma market has been comprehensively analyzed in IMARC's new report titled "Neurofibrosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor (MPNST), is a rare and aggressive cancer that arises from the cells that form the protective covering of the peripheral nerves. These tumors can occur anywhere in the body but are mostly found in the limb, torso, head, and neck regions. The symptoms of neurofibrosarcoma depend on the location of the tumor and can include painless swelling or apparent lump, limping or soreness due to compressed nerves or muscles, numbness, weakness, loss of function in the affected area, etc. The diagnosis of this illness is based on a review of the patient's medical history, clinical features, blood tests, and comprehensive physical examination. The medical professional may perform a biopsy to assess whether the ailment is MPNST by extracting a sample from the diseased site. Numerous other diagnostic procedures, including magnetic resonance imaging (MRI), positron emission tomography (PET), computerized tomography (CT), etc., are also utilized to indicate the size and location of the tumor.

The increasing cases of inherited disorders causing DNA abnormalities in the cells lined around a nerve are primarily driving the neurofibrosarcoma market. In addition to this, the rising incidence of various associated risk factors, such as pre-existing neurofibromas, previous radiation exposure (therapeutic or environmental), family history, etc., is further creating a positive outlook for the market. Moreover, the widespread utilization of ultra-low-pass whole genome sequencing for an adequate diagnosis of the disease with accurate identification of genetic variation and minimum measurement errors is also bolstering the market growth. Additionally, several healthcare companies are focusing on developing novel medications based on a better understanding of the genetics and molecular biology of soft tissue sarcomas. This, in turn, is acting as a significant growth-inducing factor. Furthermore, the inflating adoption of chemotherapy regimens, including doxorubicin, dactinomycin, cyclophosphamide, vincristine, etc., to treat unresectable and metastatic tumors is also catalyzing the market growth. Besides this, the ongoing developments in oncolytic virus vaccine therapy, which can destroy tumor cells through direct lytic activity of the virus life cycle or activating the innate immune response against cancer cells, are expected to drive the neurofibrosarcoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the neurofibrosarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurofibrosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurofibrosarcoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neurofibrosarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neurofibrosarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neurofibrosarcoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the neurofibrosarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neurofibrosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neurofibrosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of neurofibrosarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurofibrosarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurofibrosarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neurofibrosarcoma across the seven major markets?
What is the size of the neurofibrosarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neurofibrosarcoma?
What will be the growth rate of patients across the seven major markets?

Neurofibrosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neurofibrosarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurofibrosarcoma market?
What are the key regulatory events related to the neurofibrosarcoma market?
What is the structure of clinical trial landscape by status related to the neurofibrosarcoma market?
What is the structure of clinical trial landscape by phase related to the neurofibrosarcoma market?
What is the structure of clinical trial landscape by route of administration related to the neurofibrosarcoma market?

ページTOPに戻る

Table of Contents

​1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Neurofibrosarcoma - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Neurofibrosarcoma - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Neurofibrosarcoma - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Neurofibrosarcoma - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Neurofibrosarcoma - Unmet Needs

10 Neurofibrosarcoma - Key Endpoints of Treatment

11 Neurofibrosarcoma - Marketed Products
11.1 List of Neurofibrosarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Neurofibrosarcoma - Pipeline Drugs
12.1 List of Neurofibrosarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Tazemetostat - Epizyme
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Pembrolizumab - Merck & Co
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ipilimumab - Bristol Myers Squibb
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Neurofibrosarcoma - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Neurofibrosarcoma – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Neurofibrosarcoma - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neurofibrosarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neurofibrosarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neurofibrosarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neurofibrosarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neurofibrosarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neurofibrosarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neurofibrosarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neurofibrosarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neurofibrosarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neurofibrosarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neurofibrosarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neurofibrosarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neurofibrosarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neurofibrosarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neurofibrosarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neurofibrosarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neurofibrosarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neurofibrosarcoma - Access and Reimbursement Overview

16 Neurofibrosarcoma - Recent Events and Inputs From Key Opinion Leaders

17 Neurofibrosarcoma Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Neurofibrosarcoma Market – Strategic Recommendations

19 Appendix